A Cannabis-Derived Water-Soluble Preparation Lowered Eye Pressure in Rabbits but Not Monkeys

A 1981 study found that a water-soluble cannabis-derived preparation lowered intraocular pressure after intravenous administration in rabbits but not rhesus monkeys. Other routes did not reproduce that result, sharply limiting clinical interpretation.

The preparation was not identified as purified THC

Researchers tested isolated water-soluble material from Cannabis sativa. The abstract does not establish that it was equivalent to THC, CBD or a modern extract. Intravenous exposure reduced eye pressure in albino and pigmented rabbits, while monkeys showed no corresponding response.

Dose and route changed the pattern

Higher amounts produced an initial pressure increase before the decrease, and repeated daily injections produced tachyphylaxis. Topical, gastric and suppository conditions did not provide the same pressure-lowering response. A favorable result through one laboratory route therefore did not establish a practical eye medication.

Systemic and ocular responses were distinct

The study also examined systemic blood pressure, ocular fluid turnover and pharmacological blockers. Different interventions affected the initial pressure-rise phase and later pressure-lowering phase differently. These observations do not establish one mechanism accounting for every effect of the preparation.

The study illustrates why preparation identity, species and administration route must accompany a cannabis-related eye-pressure claim. It does not demonstrate treatment of human glaucoma or provide a safe product recommendation. A transient pressure change is also not evidence of preserved vision or long-term disease control.

Related: interpreting cannabis tolerance claims.

Research cited

Green K; Zalkow LH; Deutsch HM; Yablonski ME; Oliver N; Symonds CM; Elijah RD. Ocular and systemic responses to water soluble material derived from Cannabis sativa (marihuana). Current eye research (1981). doi:10.3109/02713688109001729. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A 2026 Cannabis Review Explains Why Potency, Placebo Response and Sedation Need Separate Measures

A 2026 narrative review argues that product potency is not the same as delivered THC dose and that placebo responses remain important among experienced users. Its laboratory framework also distinguishes reduced drug reinforcement from nonspecific sedation. Users can change how they inhale The review notes that participants alter inhalation patterns…

Spread the love

Read Article: A 2026 Cannabis Review Explains Why Potency, Placebo Response and Sedation Need Separate Measures

THC Antinociception Persisted Without the Same Dynorphin Signal in Tolerant Rats

A 1999 rat study found that tolerance weakened THC-related modulation of spinal dynorphin, while antinociception could still occur without the same elevated dynorphin measure. The role of a downstream signal changed with dose and adaptive state. The experiment examined spinal responses The work followed earlier findings linking acute intrathecal THC…

Spread the love

Read Article: THC Antinociception Persisted Without the Same Dynorphin Signal in Tolerant Rats

A Passiflora-Derived Fraction Reduced THC Withdrawal Signs in a Mouse Model

A 2002 mouse experiment reported fewer antagonist-precipitated withdrawal signs with a Passiflora-derived benzoflavone fraction. The finding concerns a defined experimental preparation and animal model, not a demonstrated treatment for cannabis-use disorder in people. Concurrent and acute interventions were tested Mice received repeated oral THC with or without the fraction. A…

Spread the love

Read Article: A Passiflora-Derived Fraction Reduced THC Withdrawal Signs in a Mouse Model

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us